Summary Weekly bisphosphonates are the primary agents used to treat osteoporosis. Although these agents are generally well tolerated, serious gastrointestinal adverse events, including hospitalization for gastrointestinal bleed, may arise. We compared the gastrointestinal safety between weekly alendronate and weekly risedronate and found no important difference between new users of these agents. Introduction Weekly bisphosphonates are the primary agents prescribed for osteoporosis. We examined the comparative gastrointestinal safety between weekly bisphosphonates.
complaints, erosions, and ulcers [5] . Prior evidence suggests that risedronate may have a more favorable gastrointestinal profile. Randomized controlled endoscopic studies show fewer gastric ulcers among daily risedronate users within 14 days of treatment initiation compared with daily alendronate recipients [6, 7] . Observational studies also identify fewer gastrointestinal events within 4 months of treatment initiation among new recipients of risedronate versus alendronate [8, 9] . However, more recent data from a randomized controlled trial found no difference in gastrointestinal tolerability or adverse events causing discontinuation when comparing the efficacy and tolerability of weekly dosing of these agents [10, 11] . This finding has biological plausibility as a weekly dosing interval may provide time for early esophageal lesions to heal between exposures [12] . Nonetheless, due to exclusion criteria, results from this trial may not be widely applicable to the general population of patients treated with these agents [13] . Clinicians may therefore struggle with determining the best option for osteoporosis treatment from a safety standpoint. To examine the comparative gastrointestinal safety of weekly risedronate versus weekly alendronate, we performed an observational study of new recipients of these agents eligible for a state-wide pharmaceutical benefit program. We hypothesized that we would observe no clinically significant difference in gastrointestinal safety between agents.
Materials and methods

Study cohort
The study population was identified from health care utilization data for enrollees in the Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE). This state-run program provides drug coverage without restriction for low-income residents aged 65 or more years with annual household income too high for Medicaid. Study eligibility was limited to patients with one or more claims in both Medicare and PACE in each of the three 6-month intervals preceding the index prescription. This was to ensure a minimum of 12 months of enrollment without any use of the study drugs prior to defining new use. We assembled a cohort of new recipients of weekly bisphosphonate therapy approved for osteoporosis treatment restricted to the period when both agents were available and dispensed in our cohort. Our cohort therefore included new recipients (no prescription filled for any oral bisphosphonate approved for osteoporosis management within the previous 365 days) of weekly alendronate (70 mg) and weekly risedronate (35 mg) between June 16, 2002 (date risedronate first dispensed in our cohort) and August 31, 2005 (Fig. 1) . We excluded residents of nursing homes (where prescription data may not be complete), patients with a Medicare claim for Paget disease (International Classification of Diseases, Ninth Revision, Clinical Modification code 731.0), use of alendronate solution, and those with a history of any other bisphosphonate use (e.g., etidronate, which is not approved for osteoporosis management in the United States) within the year prior to index prescription. Our data included all PACE beneficiaries that met eligibility criteria. At the time of analysis, we had complete Medicare data through to December 31, 2005 .
Outcomes
Our primary outcome was hospitalization for upper gastrointestinal bleed (hemorrhage or perforation) defined by primary discharge diagnosis in Medicare claims using previously validated criteria [14, 15] . Secondary outcomes included outpatient diagnosis for gastrointestinal diseases (peptic ulcer disease, gastrointestinal reflux disease, or gastritis), outpatient diagnosis for gastrointestinal symptoms (abdominal pain, dyspepsia, heartburn, nausea, or vomiting), upper gastrointestinal endoscopy, and use of gastroprotective agents (H2-receptor antagonists, proton pump inhibitors, misoprostol, or sucrulfate). Finally, we examined switching between agents as a general marker of side effects associated with initial therapy. Table 3 of the Appendix provides specific diagnostic and procedural codes used in our study.
Covariates
Patient demographics were determined at the time of treatment initiation and other variables by medical and pharmacy claims within the year prior to treatment initiation. Covariates included factors plausibly related to upper gastrointestinal morbidity [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] such as demographics (age, sex, race), upper gastrointestinal-related (e.g., in-and outpatient gastrointestinal disease, varices, Mallory-Weiss syndrome), osteoporosis-related diagnoses (e.g., kyphosis, osteoporosis, vertebral fracture), comorbidities (e.g., alcohol abuse, coagulation defects, chronic liver disease, Crohn's disease, gastroenteritis, depression, overweight/obesity), drug use (e.g., antiplatelet/antithrombotic, gastroprotective agents, glucocorticoids, selective Cox-2 inhibitors, other nonsteroidal antiinflammatory, number of generics), and prior hospitalization. We also included calendar time (month and year) of the index prescription to adjust for potential secular trends in prescribing or coding. Table 4 of the Appendix lists all variables, definitions, and coding. If a record of a specific diagnosis, procedure, or prescription was lacking, patients were coded as not having these characteristics. As a result of this coding rule, there were no participants for whom exposure, confounder, or outcome information was missing.
Statistical analysis
Descriptive characteristics and covariates were summarized by user group. We used Cox proportional hazard models to compare the rates of occurrence of each outcome between weekly risedronate and weekly alendronate, censoring only on the date of death or end of follow-up (120 days following treatment initiation). We therefore followed surviving patients throughout the 120-day period of follow-up, regardless of whether or not prescription refills suggested continued exposure. We tested proportional hazards assumptions by including an interaction term between exposure and the log of time, finding no violations over the 120-day period of follow-up.
Alendronate was selected as the reference category in all Cox proportional hazard models. We developed exposure propensity scores for risedronate prescribing using logistic regression to adjust for confounding. Propensity score methods of adjustment are comparable to conventional multiple variable adjustment [26] . However, propensity score methods of adjustment reduce the number of covariates included in the outcome model and are thus advantageous when studying rare outcomes [27, 28] . We also restricted the adjusted analyses to recipients with overlapping propensity scores; minimum propensity scores equal to the lowest value observed among risedronate recipients ("exposed") and maximum value equal to that observed among alendronate recipients ("unexposed"). Risedronate propensity score quintiles (four dummy variables) were used to adjust for confounding in Cox proportional hazard models.
In sensitivity analyses, we examined two composite outcomes: (1) any upper gastrointestinal diagnosis or procedure and (2) any gastrointestinal outcome considered, as well as modified our outcome coding for upper gastrointestinal procedure by restricting it to the most commonly identified codes in our cohort. In addition, we completed analyses stratified by age, defined by the median age of our cohort (less than or equal to median age versus greater than median age) and history of gastrointestinal events (gastrointestinal neoplasm or any upper gastrointestinal diagnosis, symptom, or procedure; versus none) within the year prior to treatment initiation. Analyses were completed using SAS 9.1 (SAS, Cary, NC, USA).
In a secondary analysis, we additionally censored patients on the first day of switching agents, losing drug plan eligibility, entering a nursing home, or discontinuing drug therapy (last date covered by drug plus 15 days, allowing for 30-day gaps between prescriptions) [13] . Finally, we examined the extent of residual confounding necessary to account for a null finding if in fact differences in hospitalization for gastrointestinal bleed exist between agents [29] . In applying the "array approach" (Microsoft Excel file available at www.drugepi.org) [29] , we allowed the relative risk between the possible unmeasured confounder and gastrointestinal bleed to vary from 1 to 5.5 and the prevalence of this unmeasured confounder among risedronate recipients (exposed) to vary from 0% to 50%. We produced separate figures to compare results assuming that the prevalence among alendronate recipients (unexposed) was 10%, 20%, or 40%. We were specifically interested in examining the extent of confounding if the true relative risk was 0.70 (based on a previously reported estimate for a broad gastrointestinal outcome where the hazard ratio was 1.4 for alendronate compared to risedronate) [9] .
The Partners HealthCare Institutional Review Board approved this project. Data Use Agreements are in place from PACE and the Centers for Medicare and Medicaid Services.
Results
Study cohort
Of 12,042 new recipients of weekly bisphosphonates identified, 1,622 were excluded (1, 196 nursing home residents, 364 treated before the first dispensing of risedronate in our cohort, 63 dispensed alendronate solution, 19 had other previous bisphosphonate use, and 33 Paget disease). We studied the remaining 10,420 new recipients ( Table 1 ). The mean age of our cohort was 78.7 years (SD=6.9, range 65-101, median=79), 95% women and 95% Caucasian. There was little evidence of potential confounding between alendronate and risedronate recipients, with each group being of similar age and having similar disease risk profiles (prevalence of comorbidities). However, slightly more risedronate recipients had a background history of gastrointestinal events (38% versus 35%) and had been treated with gastroprotective agents (38% versus 34%). In contrast, more alendronate recipients (23% versus 20%) had been hospitalized in the year prior to their index prescription. These differences disappeared within risedronate propensity score quintiles, with a mean difference between quintiles of 0.1% for gastrointestinal event history, 0.3% for gastroprotective agents, and 0.2% for previous hospitalization (Table 5 of the Appendix).
Comparative gastrointestinal safety
We observed 31 hospitalizations for upper gastrointestinal bleed (0.91 per 100 person-years) within 120 days of treatment initiation. We found no difference between the rates of hospitalization for upper gastrointestinal bleed (HR, 1.12; 95%CI, 0.55 to 2.28) or any other outcome considered in our primary analyses (Table 2) . Although the number of events was too small to examine differences in hospitalization by gastrointestinal history or among those aged younger than 80 years, we found no difference between agents among those aged 80 or more years (2.58 bleeds per 100 personyears of follow-up; HR, 0.97; 95%CI, 0.45 to 2.08).
Using the array approach, it is unlikely that our null finding is due to residual confounding. For example, if an unmeasured confounder has a strong relationship with our outcome (relative risk of 5.0) and its prevalence is 20% among alendronate recipients, then its prevalence would need to be twofold (over 40%) higher among risedronate recipients to bring the "fully adjusted" estimate from the observed value of 1.12 to 0.70 (Fig. 3 of the Appendix). Similarly, if the prevalence of the confounder was only 10% (instead of 20% as described in the figure) among alendronate recipients, the prevalence of the confounder would need to be more than twofold higher (22% or more) to bring an observed estimate of 0.95 (e.g., observed for outpatient visits for gastrointestinal disease in our study) to a fully adjusted estimate of 0.7 (figure not shown).
Overall, we document no large differences between agents for secondary or composite outcomes, except that risedronate users had lower switching rates (Fig. 2) . Lower switching rates among risedronate versus alendronate users was also observed in the secondary ("on-treatment") analysis. In the main on-treatment analysis (hospitalization for gastrointestinal bleed), 59% were censored at the end of the 120 days of observation, and 39% were censored due to stopping treatment. Patients persisted with therapy for a mean of 87.6 days (SD=41.2), and there was no difference in persistence with therapy between agents (P=0.17). Among those with known history of gastrointestinal events, we found that rates for upper gastrointestinal endoscopic procedures were lower among risedronate (HR, 0.70; 95% CI, 0.49 to 0.99) compared with alendronate recipients. However, when endoscopies and switching between therapies were combined with upper gastrointestinal diagnoses and symptoms within 120 days after treatment initiation as the outcome, we found no large difference between agents (HR, 0.98; 95%CI, 0.92 to 1.04). Similar results were found when we examined endoscopies using the more restrictive coding (data not shown).
Discussion
A recent systematic review concluded that there is no difference in the rates of upper gastrointestinal events between alendronate or risedronate and placebo [30] . Our findings further suggest that there is no important difference in the gastrointestinal safety between weekly risedronate and weekly alendronate tablets. We did an English language [10] . Randomized controlled trials such as the FACT establish drug efficacy within defined patient populations, often not representative of those who may benefit from pharmacotherapy or how the agents, are used in practice [31] . We studied a much larger and older cohort of new bisphosphonate recipients, and our findings complement and corroborate FACT results.
Although our study design may allow for wider generalizability compared to prior studies [8] [9] [10] , we are limited because our study relies entirely on claims data. Data not captured within administrative claims may be associated with gastrointestinal outcomes. For example, we lacked data on cigarette smoking [23] , alcohol consumption, body mass index [18] , and the use of over-thecounter products such as nonsteroidal antiinflammatory agents or gastroprotective medications. More risedronate recipients in our study had a background history of gastrointestinal disease and had been prescribed a gastroprotective agent. Channeling of patients with gastrointestinal disease to risedronate versus alendronate has also been observed in a cohort of chronic glucocorticoid users [32] . If risedronate recipients in our study also had more risk factors for upper gastrointestinal disease not measured by our data, our null findings may be attributed to residual confounding. However, using the "array approach" for sensitivity analysis [29] , a strong confounder (e.g., relative risk of 5.0) and large imbalances between exposure groups (e.g., 20% alendronate versus 40% risedronate) would be required to account for our null findings. Instead, we document very small differences in background history of gastrointestinal disease (about 3%) using data measured in healthcare utilization data. We therefore do not believe that the differences between unmeasured factors such as alcohol consumption, cigarette smoking, or body mass We found a consistent lack of difference in risk between agents among those with no gastrointestinal history. However, among the smaller cohort of patients with history of gastrointestinal events, risedronate recipients had lower rates of endoscopy. Although the definition of our primary outcome (hospitalization for upper gastrointestinal bleed) has been validated, we cannot rule out the possibility that outpatient diagnoses and symptoms identified in claims data reflect care to "rule-out" upper gastrointestinal disease or follow-up visits for preexisting conditions. It is thus difficult to make strong conclusions based on this secondary endpoint alone. It could be that endoscopy represents more severe gastrointestinal side effects, or it could represent a differential in practice style between physicians who prescribe alendronate versus risedronate. Indeed, after combining endoscopy with outpatient diagnoses for upper gastrointestinal disease or symptoms, we observed no difference between agents. Therefore, the clinical importance of differences in the rates of upper gastrointestinal endoscopy identified by our study is unclear and caution in interpretation is advised. In addition to those already mentioned, four limitations are worth noting. First, by studying a cohort of frail older adults from Pennsylvania, our results may not be generalizable to all users of these agents, such as younger patients with chronic glucocorticoid treatment. However, given that oral bisphosphonates are largely prescribed to treat primary osteoporosis, we believe our study population to be a significant strength. We were able to study a large cohort of older adults with complete drug coverage without restrictions (alendronate and risedronate are fully covered with the same co-payment), and older frail adults are at the highest risk for gastrointestinal disease [19] .
Second, our study database only contained claims data to determine gastrointestinal outcomes and may thus have misclassified some events. Prior studies have found that gastrointestinal adverse events are one of the main reasons for discontinuing bisphosphonate treatment for osteoporosis [33] [34] [35] [36] . In our secondary (on-treatment) analysis, we document that 39% were censored due to lack of persistence with treatment and another 1% switched between agents. Although there were no differences in persistence or reasons for censoring between agents, we may have underestimated the extent of gastrointestinal side effects resulting from bisphosphonate treatment. For these reasons, we completed our primary analyses using an "intention-to-treat scenario" and followed surviving patients for 120 days. This analytic approach allows for a time lag between when a patient's symptoms appear (may stop taking medication) and presentation in a physician's office with an upper gastrointestinal complaint (requires time to book an appointment with a physician or to be referred for endoscopy). We also focused on hospitalization for upper gastrointestinal bleed using previously validated criteria [14, 15] as our primary outcome, and there is no reason to believe that there would be differential misclassification in hospitalizations between bisphosphonate therapies.
Third, our study is limited by statistical power due to few events observed for our primary outcome (hospitalization for gastrointestinal bleed). One method to increase the number of events under study would be to lengthen the period of observation beyond 120 days. However, prior research has documented that upper gastrointestinal problems from oral bisphosphonate therapy occur early in the time course of treatment [6, 7] , and thus, 120 days is an appropriate risk window of observation. Extending the length of observation could also introduce information bias such as depletion of susceptibles [37] . Similarly, we were concerned about the potential for informative censoring using an on-treatment analysis, whereby patients experiencing early gastrointestinal discomfort stop taking their bisphosphonate and would thus be censored from analysis before a signal is detected in claims data.
Finally, we were unable to examine the comparative gastrointestinal safety of newer oral bisphosphonate formulations. Ibandronate received FDA approval for osteoporosis treatment using monthly dosing in March 2005. The prolonged dose-free interval may result in fewer gastrointestinal events [12] , but this remains to be documented by comparison with weekly bisphosphonates in prospective studies. Risedronate also received FDA approval in April 2007 for monthly dosing (75 mg tablet on two consecutive days) to treat postmenopausal osteoporosis. Future studies that examine the comparative gastrointestinal safety of oral bisphosphonates are of interest.
In conclusion, we found no important difference in upper gastrointestinal safety between weekly alendronate and weekly risedronate. Future studies may help to further identify if differences in gastrointestinal safety exist between oral bisphosphonates, particularly by dosing interval (e.g., weekly versus monthly) and among patients with different risk profiles (e.g., younger age and gastrointestinal risk). [14] and Spain [15] have found that over 90% of patients with one of these codes as their primary hospital discharge diagnosis were indeed hospitalized for upper gastrointestinal bleed b Although we are unaware of validation data for outpatient diagnostic codes, the positive predictive value of using ICD-9-CM procedural codes for upper gastrointestinal endoscopy has been reported to be over 97% [38] . We supplemented these ICD-9-CM procedural codes with CPT-4 codes to improve the sensitivity of our estimates [8] . Of those identified as having had an upper gastrointestinal endoscopy in our study (N=224), 5% had ICD-9-CM codes only, 41% had CPT-4 codes only, and 54% had both types of codes. In a sensitivity analysis, we restricted coding to the most commonly identified codes (CPT-4 codes 43235, 43239; N=180) Fig. 3 Sensitivity analysis of residual confounding using the array approach for our primary outcome (hospitalization for upper gastrointestinal bleed). To facilitate interpretation by the reader, we have maintained the notation used in the explanatory article and Excel program that we modified (available at www.drugepi.org) to produce this figure [29] . ARR apparent exposure relative risk, i.e., the relative risk (hazard ratio) observed in the current study (risedronate versus alendronate), fixed at 1.12. P C0 prevalence of counfounder among unexposed (alendronate), fixed at 20% in this example. P C1 prevalence of confounder among exposed (risedronate) group, varied from 0% to 50% in the figure. RR CD association between confounder and disease outcome, varied from 1.0 to 5.5 in figure. RR fully adjusted or "true" exposure relative risk. Blue line no confounding present, prevalence of confounder same among alendronate and risedronate recipients
